title: Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal.
authors.affiliation: Immunodeficiency Clinic, Toronto General Hospital, Toronto, Ontario, Canada.
authors.forename: Alice L
authors.initials: AL
authors.lastname: Tseng
authors.forename: Jonathan
authors.initials: J
authors.lastname: Luetkehoelter
authors.forename: Sharon L
authors.initials: SL
authors.lastname: Walmsley
mesh_terms: D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000925:Anticoagulants / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000069446:Atazanavir Sulfate / Q000008:administration & dosage / Q000493:pharmacokinetics; D001774:Blood Chemical Analysis; D000069547:Cobicistat / Q000008:administration & dosage / Q000493:pharmacokinetics; D000069454:Darunavir / Q000008:administration & dosage / Q000493:pharmacokinetics; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D019438:Ritonavir / Q000008:administration & dosage / Q000493:pharmacokinetics; D014859:Warfarin / Q000008:administration & dosage / Q000493:pharmacokinetics
chemical_list: D019380:Anti-HIV Agents; D000925:Anticoagulants; D000069446:Atazanavir Sulfate; D014859:Warfarin; D000069547:Cobicistat; D019438:Ritonavir; D000069454:Darunavir